DANIEL STORCH: Open Payments
NPI 1790740413 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,059 in 47 payments from 9 companies in 2025. Trend: 2023 $1,260 · 2024 $1,207 · 2025 $1,059
Food & beverage: $1,059
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 13 | $310 |
| ABBVIE INC. | 11 | $192 |
| E.R. Squibb & Sons, L.L.C. | 8 | $166 |
| Teva Pharmaceuticals USA, Inc. | 6 | $140 |
| Janssen Pharmaceuticals, Inc | 3 | $86 |
| Vanda Pharmaceuticals Inc. | 2 | $66 |
| Alkermes, Inc. | 2 | $47 |
| Axsome Therapeutics, Inc. | 1 | $31 |
| Lundbeck LLC | 1 | $21 |
Products named: INGREZZA, VRAYLAR, COBENFY, AUSTEDO XR, INVEGA SUSTENNA, HETLIOZ, ARISTADA, Auvelity.
Industry payments across MD — which companies pay providers there.
